Clinical Trial Update: A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ARRY-382 in combination with pembrolizumab in advanced solid tumors; the study (Phase 1/2) has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ARRY-382 (ARRY-382)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Pfizer | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-06-16